Immix Biopharma Inc. - IMMX Net earnings per share for the last four quarters

Official company branding of Immix (IMMX)

Immix Biopharma, Inc. (IMMX) is developing a unique targeted therapy network where the IMX-110 platform and partner clinics create a closed-loop treatment cycle. The available price action vector based on EPS (ttm) is -5.60, which complements data regarding the development of agents against solid tumors in the US to improve drug delivery. Business prospects rely on the CAR-T system (NXC-201), which retains myeloma patients within FDA-approved centers.

Immix Biopharma (IMMX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

IMMX (Immix Biopharma Inc.): analytical breakdowns and indicator data

Initial company analysis:IMMX, Immix Biopharma, Inc.
Mass-produced product of Immix Biopharma

Investors must assess risks via the annual volatility of TTM net income per share, which measures EPS growth rates over the last 12 months to determine operational resilience. The current value of -5.60 reflects the financial dynamics of Immix Biopharma, Inc. (IMMX), where the absence of commercial sales renders this indicator a marker of speculative expectations regarding drug development rather than the actual pricing power of the business.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months